TABLE 2 Reactivity of PNL2, HMB-45, and Anti Melan A with Melanocytic Tumors on Paraffin-Embedded Sections
From: PNL2, a New Monoclonal Antibody Directed against a Fixative-Resistant Melanocyte Antigen
Tumor Type | PNL2 (positive/tested) | HMB-45 (positive/tested) | Anti Melan A (positive/tested) |
|---|---|---|---|
Benign lesions | |||
Nevi | |||
Dermal | 9/9* | 8/9* | 9/9 |
Junctional | 1/1 | 1/1 | 1/1 |
Compound | 9/9* | 9/9* | 9/9 |
Congenital | 1/1* | 1/1* | 1/1 |
Spitz | 3/3* | 3/3* | 3/3 |
Desmoplastic | 1/4 | 1/4 | 1/4 |
Pigmented spindle cells (Reed) | 3/3 | 3/3 | 3/3 |
Common blue | 4/4 | 4/4 | 4/4 |
Lymph node capsular nevi | 4/4⊗ | 1/4⊗ | 4/4⊗ |
Dysplastic | 1/1 | 0/1 | 1/1 |
Lentigo simplex | 8/8 | 8/8 | 8/8 |
Total | 44/47 | 39/47 | 44/47 |
Malignant lesions | |||
Melanomas | |||
Primary | |||
Lentigo maligna | 7/7 | 7/7 | 7/7 |
Superficial spreading | 8/8 | 8/8 | 8/8 |
Acral lentiginous | 8/8 | 8/8 | 8/8 |
Nodular | 4/4 | 3/4 | 3/4 |
In congenital melanocytic nevus | 1/1 | 1/1 | 1/1 |
Mucosal | 1/1 | 1/1 | nd |
Desmoplastic | 0/3 | 0/3 | 0/3 |
Metastatic | |||
Skin | 10/10 | 9/10 | 9/10 |
Lymph node | 6/6 | 6/6 | 6/6 |
Pleural effusion | 1/1 | 1/1 | 1/1 |
Total | 46/49 | 44/49 | 43/48 |
Total | 90/96 | 83/96 | 87/95 |
